| | ||||||||||
| 1 | INN | Class | Route (list) | PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693) | Primary Target and PDB code of Protein-Drug complex | Targets from DrugCentral | Links | |||
| LENIOLISIB
| LENIOLISIB | ANTINEOPLASTIC | ORAL | Tmax 1 HOUR VD 28.5 LITER PPB 94.5 PERCENT HT 10 HOUR SOLUBILITY DECREASING SOLUBILITY OBSERVED WITH INCREASING PH | PHOSPHOINOSITIDE 3-KINASE DELTA (PI3K DELTA) PDB 5O83 (DISCOVERY OF CDZ173 (LENIOLISIB), REPRESENTING A STRUCTURALLY NOVEL CLASS OF PI3K DELTA-SELECTIVE INHIBITORS) LIGAND CODE = 9NQ (link to the list of PDB complexes) Download experimental 3D coordinates of 9NQ with added hydrogens | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform PK3CD O00329 | EMA | |||
| 2 | INN | Class | Route (list) | PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693) | Primary Target and PDB code of Protein-Drug complex | Targets from DrugCentral | Links | |||
| SORAVTANSINE
| SORAVTANSINE MIRVETUXIMAB SORAVTANSINE-GYNX | NATURAL MOLECULE (link) ANTINEOPLASTIC | INJECTION | Cmax 5.2 NANOMOLAR PPB 99 PERCENT Cl 13.8 LITER / HOUR HT 67.2 HOUR | TUBULIN | TUBULIN TBB1_HUMAN INHIBITOR P04350 | EMA | |||
